Kaline Pereira

Trastuzumab Deruxtecan in Patients With <i>HER2</i>-Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial

Kōichi Goto, Yasushi Goto, Toshio Kubo et al. · Journal of Clinical Oncology · 2023 · 299 citations · Full text

Medicine, Oncology, Pharmacology +17

Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial

Egbert F. Smit, Enriqueta Felip, Dipesh Uprety et al. · The Lancet Oncology · 2024 · 156 citations · Full text

Medicine, Oncology, Pharmacology +16

LBA55 Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutant metastatic non-small cell lung cancer (NSCLC): Interim results from the phase 2 DESTINY-Lung02 trial

Keiko Goto, K. Sang-We, Takafumi Kubo et al. · Annals of Oncology · 2022 · 60 citations · Full text

Medicine, Oncology, Pharmacology +17

1321MO Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic non–small cell lung cancer (NSCLC) with and without brain metastases (BMs): Pooled analyses from DESTINY-Lung01 and DESTINY-Lung02

B.T. Li, David Planchard, Kōichi Goto et al. · Annals of Oncology · 2023 · 37 citations · Full text

Medicine, Oncology, Pharmacology +12

Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02—A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC

Pasi A. Jänne, Yasushi Goto, Toshio Kubo et al. · Journal of Thoracic Oncology · 2025 · 16 citations · Full text

Medicine, Oncology, Pharmacology +14